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Introduction
All causes of anaemia give a reduction of 
haemoglobin level and red blood cells value and 
haematological problems have a high impact 
on the quality of life. Anaemia is defined as a 
condition in which the body has a decreased 
number of circulating erythrocytes, or Red 
Blood Cells (RBCs), that become insufficient 
to meet the body’s physiologic needs. 
Consequently, anaemia can also be defined as 
a decreased hemoglobin concentration or RBC 
mass compared with age-matched controls. The 
World Health Organization (WHO) defines 
anaemia as a Haemoglobin (Hb) less than 13 g/
dL in adult men and less than 12 g/dL in non-
pregnant adult women [1]. 
Iron deficiency (ID) and Iron-Deficiency 
Anaemia (IDA) are globally recognized, in daily 
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Abstract
Background: Anaemia is a frequent co-morbidity in old patients affected by chronic heart failure and/or respiratory 
diseases. Using the Heart Rate Variability (HRV) analysis is possible to provide an evaluation of the safety and the 
effectiveness of intervention.
Objective: To evaluate the efficacy and safety of Ferric Sodium EDTA in combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine (Ferachel forte®) 2 tabs/day for 24 days in elderly patients with secondary 
anaemia, by exploring the HRV frequency domain.
Methods: In 45 elderly patients with secondary anaemia and/or low-moderate kidney failure, laboratory values after 
administration of Ferric Sodium EDTA, 2 tabs a day, in combination with vitamin C, folic acid, copper gluconate, zinc 
gluconate and selenomethionine (Ferachel forte®) for 24 days (N=16 patients) or ferrous gluconate 63 mg/day added to 
saline solution, administered using intravenous access during the hospitalization period of 15 ± 5 days (N=29 patients) 
were evaluated. Also, ECG signals and bioelectrical impedance (BIA) were measured.
Results: Oral iron supplementation with Ferric Sodium EDTA, in combination with vitamin C, folic acid, copper gluconate, 
zinc gluconate and selenomethionine (Ferachel forte®) confirmed to be effective and safe about the cardiovascular risk 
in old patients. This study showed the real superiority of the oral administration about the cardiovascular risk in elderly 
patients in comparison with intravenous administration of ferrous gluconate. 
Conclusion: This study confirms that Ferric Sodium EDTA combination (Ferachel forte®) can be a valid alternative to ferrous 
gluconate intravenous therapy (gold standard) in the treatment of secondary anaemia in elderly patients. In fact, during 
the treatment, efficacy results have been maintained without statistically significant variations about cardiovascular risk, 
evaluated by exploring the HRV frequency domain. 
Keywords: Anaemia, cardiovascular risk, ferric sodium EDTA, spectral analysis, HRV frequency domain, elderly, 
kidney failure
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populations, are recognized to be 
associated with a worsening of nutritional 
state. Furthermore, in depressive disorders 
occurs dysregulation of the neuroendocrine 
and sympathetic nervous systems, potentially 
affecting erythropoiesis [3,5,6].
Iron malabsorption is also relatively frequent 
in the elderly and can be affected by Helicobacter 
pylori (HP) infection, autoimmune atrophic 
gastritis, celiac disease, IBD, and long-term use 
of Proton Pump Inhibitors (PPI) [3,5].
Several studies evaluated anaemia frequency 
in older adults, showing a range from 8% to 
25%, with increased percentage in subjects 
older than 85 years old. In this population, 
anaemia can influence mortality and cognitive/
physical performance, increasing number of falls 
and hospitalizations. Therefore, the evaluation 
of iron blood level and the relative treatment or 
follow-up is crucial [3,5].
Recent studies underline that iron 
administration is associated with improvements 
of cardiovascular outcomes and quality of life 
[2,7,8].
Using the Heart Rate Variability (HRV) 
analysis of the spectral components in the 
frequency domain is possible to explore the 
neurovegetative system. Numerous physiological 
conditions and diseases have an impact factor 
on the dimension of the area of each peak of 
frequency range on the HRV power spectrum. 
Some studies have used spectral HRV and blood 
pressure variability analysis in a large group 
of patients and it has been observed that the 
increase in total HRV and LF power is associated 
with survival, while the progressive decreases of 
HRV have been associated with deterioration 
and death. Alterations of the spectral analysis are 
correlated with the severity of the disease, the use 
of this method for the assessment of the state of 
cardiac and non-cardiac diseases, could provide 
an evaluation of the prognosis and determine 
the effectiveness of intervention [9,10].
  Aim of the study
The aim of this study is to confirm the 
efficacy and safety of Ferric Sodium EDTA in 
combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) 2 tabs a day for a treatment 
period of 24 days, in elderly patients with 
secondary anaemia, about cardiovascular risk 
clinical practice, as frequent medical conditions. 
ID is defined as a level’s reduction of total body 
iron, especially iron stores, with preservation of 
levels of erythroid iron. IDA is a more severe 
condition in which low levels of iron are 
associated with anaemia and the presence of 
microcytic hypochromic red cells [2]. 
Anaemia is a common, multi-factorial, 
relatively mild condition in elderly, with Hb 
levels near 10-11g/dL in most subjects. However, 
it can be associated with a variety of adverse 
outcomes, including longer hospitalization, 
disability, and increased mortality risk [3].
Regarding Hb threshold to be used to define 
anaemia in elderly individuals, discussions have 
been reported, since WHO criteria were based 
on statistical distributions in reference samples 
that did not include individuals >65 years of 
age. Several studies reported that a Hb value 
<12 g/dL is commonly considered indicative 
of anaemia in elderly of both sexes, since Hb 
values in apparently healthy elderly individuals 
are generally lower than those in younger adults 
and the differences between males and females 
tend to disappear with aging [3,4].
In old patients, the main causes of anaemia 
are Iron Deficiency Anaemia (IDA) and 
anaemia of chronic diseases (or functional ID), 
that can be affected by several factors, including 
malnutrition, delay gastric emptying and occult 
blood loss [5]. 
In elderly, Chronic Gastrointestinal (GI) 
diseases represent the most frequent causes 
of ID and IDA, leading to both iron loss and 
malabsorption. Chronic upper and lower 
GI blood losses can be related to a variety of 
pathologies like esophagitis, gastritis, peptic 
ulcer, Inflammatory Bowel Disease (IBD), 
neoplastic disease, and ano-rectal lesions, such 
as haemorrhoids. Furtherly, GI bleeding is 
increased in multimorbidity patients, taking 
concomitantly chronic medications, like Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs) 
and/or antithrombotic therapies [3,5].
Malnutrition can be associated with 
inadequate dietary iron intake and absorption 
and can be worsen by decline of biological 
and cognitive functions, i.e. a reduction of 
appetite and of taste sensation. Also, depressive 
syndromes, particularly frequent in older and 
quality of life, explored by HRV frequency 
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control index of activation of the sympathetic 
system, the HF (high frequency) which includes 
the frequencies between 0.15-0.4 Hz, that are 
associated with parasympathetic activation 
index, and reflect the vagal modulation of the 
sinus rhythm associated with the respiratory 
arrhythmia and finally the Total Power which is 
the sum of the three peaks or the sum of the 
single spectral powers (VLF+LF+HF) [9,10].
Statistical analysis is performed using Paired 
T-test with Sigmastat v. 3.5 analysis program. 
Differences were considered significant when 
P<0,05.
Results
Data collected in this study confirm that 
oral treatment with Ferric Sodium EDTA, in 
combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) at the dosage of 60 mg (2 tabs 
a day) is an efficacy and safety treatment as 
preliminary referred. Both results in hemoglobin 
(Hb) and sideraemia levels showed that 
treatment with oral iron supplementation for 24 
days is as effective as intravenous iron infusion, 
administrated during hospitalization period (15 
± 5 days). In particular, Hb levels raised from 
9.5 ± 1.3 g/dL to 11.7 ± 1.9 g/dL (p=0.001) in 
the group treated with Ferric Sodium EDTA 
(TABLE 1). The corresponding increase in Hb 
levels in intravenous iron-treated group was 
from 8.9 ± 1.5 g/dL to 9.9 ±1.9 g/dL (p=0.001; 
TABLE 2). Similar results were obtained for 
sideraemia levels: from 19.5 ± 5.6 mcg/dL to 
53.8 ± 25.9 mcg/dL (p=0.001; TABLE 1) for 
oral iron administration group; and from 19.6 ± 
12.2 mcg/dL to 37.1 ± 21.9 mcg/dL (p=0.001; 
TABLE 2) for intravenous therapy group.
  Safety results
Treatment with Ferric Sodium EDTA in 
combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) did not modify ECG 
parameters, without bringing concerns about 
high liquid amounts administered to such a 
sensitive patient population, such is the elderly 
patient with low-moderate kidney failure 
(TABLE 1). 
Data showed that intravenous iron 
supplementation exposes patients to a greater 
water supply due to iron dilution into saline 
domain evaluation. 
Methods
45 elderly patients (age 79,4 ± 10,1 years old) 
with a recent diagnosis of secondary anaemia due 
to iron deficiency and/or low-moderate kidney 
failure were enrolled. The patients were divided 
into 2 groups: 16 patients were treated with 
oral administration of Ferric Sodium EDTA 2 
tabs a day, corresponding to 60 mg of iron, in 
combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) for 24 days; 29 patients were 
treated with ferrous gluconate 63 mg/day 
added to saline solution administered using 
intravenous access during the hospitalization 
period of 15 ± 5 days. The enrolled patients had 
low-moderate kidney failure (mean creatinine 
value: 1,1 ± 0,6 mg/dL in the group with 
oral administration of Ferric Sodium EDTA 
combination and 1,4 ± 1 mg/dlL in the group 
with intravenous administration of ferrous 
gluconate). Improvement of laboratory values, 
such as haemoglobin and sidereamia level, and 
electrocardiographic trace with a length of 2-5 
minutes before and after the administration of 
Ferric Sodium EDTA combination or ferrous 
gluconate, were evaluated. 
Also, the ECG signal and the Bioelectrical 
Impedance (BIA) were measured. For the ECG 
signal analysis, Cardio CE palm version 2.0 
(XAI-Medica) was used to register standard 
ECG and beat to beat ECG for Heart Rate 
variability evaluation. The Bioelectrical 
Impedance Analysis (BIA) has been analyzed 
with the Bodygram PRO 3,0 (Akern). 
Using a short registration of the 
electrocardiographic trace the T-peak to T-end 
index (Tp/Te) and the Qt correct interval (QTc) 
have been measured [11].
Using a short registration of the 
electrocardiograph with a length of 2-5 min, 
the spectral analysis reveals three main peaks, 
describable as the VLF (very low frequency) 
that includes very low frequencies with values 
between 0 and 0.04 Hz that are influenced by 
the regulation of the temperature and from 
the humoral systems, the LF (low frequency) 
that includes low frequencies between 0.04-
0.15 Hz, that are associated both to the 
sympathetic modulation and to the sympatho-
vagal modulation depending on the baroceptive 
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gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) is a new iron formulation used 
for oral treatment of patients with secondary 
anaemia. Ferric Sodium EDTA is a novel iron 
source that already reported large efficacy and 
safety data in several setting, such as anaemic 
pregnant women [12-14], anaemic pre-school 
and school-aged children and adolescents [15-
19]. 
In addition, several meta-analyses concluded 
that Ferric Sodium EDTA, already as single 
component, is highly effective in controlling 
iron deficiency and reducing the prevalence 
of iron-deficiency anaemia in men, women, 
and children [20-22]. Furtherly, Ferric 
Sodium EDTA is recommended for the mass 
fortification of high-phytate cereal flours and 
for sauces with a high peptide content (e.g. fish 
sauce, soy sauce), by the WHO Guidelines on 
food fortification with micronutrients.
The use of Ferric Sodium EDTA in 
combination with vitamin C, folic acid, copper 
gluconate, zinc gluconate and selenomethionine 
(Ferachel forte®) was evaluated in elderly patients 
with secondary anaemia due to iron deficiency 
and/or low-moderate kidney failure, since this 
solution. Intravenous iron supplementation gave 
a statistically significant variation of the T-peak 
to T-end value that represents a predictive 
parameter of arrhythmic risk (FIGURE 1). 
This trend is confirmed by the evaluation of the 
difference in the electrical resistance measured 
using a bioimpedenziometric test (FIGURE 2).
More interesting data are noted analyzing 
electrocardiographic results regarding HRV 
frequency domain after the treatment with Ferric 
Sodium EDTA combination at the dosage of 60 
mg/day for 24 days (TABLE 3 and FIGURE 
3), because this positive trend is confirmed by 
the absence of statistically significant reduction 
(p=0.097) of the vagal tone using the Fast Fourier 
Transformation analysis or FFT-HF (TABLE 3) 
and the relative statistically significant reduction 
(p=0.049) of the vagal tone using the Auto-
regressive Analysis or AR-HF (TABLE 3 and 
FIGURE 3). In the patients enrolled in this 
study, the oral administration confirms the safety 
of the treatment at high dosage (2 tabs a day).
Discussion
The therapy with Ferric Sodium EDTA, in 
combination with vitamin C, folic acid, copper 
TABLE 1. Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, 
zinc gluconate and selenomethionine (Ferachel forte®) (2 tabs/day, for 24 days); n.a.=not 
available. The data are expressed as value ± Standard Deviation (DS).
Control Effect p-Value
Hb (g/dL) 9.5 ± 1.3 11.7 ± 1.9 0.001
Fe++ (mcg/dL) 19.5 ± 5.6 53.8 ± 25.9 0.001
RR (msec) 778.5 ± 179.1 814.5 ± 172.9 0.125
LF (msec) 600.5 ± 626.1 1442.4 ± 3017.3 0.625
HF (msec) 854.9 ± 909.9 2780.1 ± 6137.1 0.688
Tp-e (msec) 96.8 ± 14.9 95.8 ± 12.9 0.844
QTc (msec) 317.3 ± 28.6 318.3 ± 30.6 0.625
Tp-e/QTc 0.304 ± 0.04 0.301 ± 0.04 0.844
Resistance (Ω) n.a. n.a. n.a.
Reactance (Ω) n.a. n.a. n.a.
TABLE 2. Intravenous ferrous gluconate 63 mg/day into saline solution 500 mL, 
administered during the hospitalisation period (15 ± 5 days).
Control Effect p-Value
Hb (g/dL) 8.9 ± 1.5 9.9 ± 1.9 0.001
Fe++ (mcg/dL) 19.6 ± 12.2 37.1 ± 21.9 0.001
RR (msec) 755.0 ± 243.4 779.0 ± 234.4 1.000
LF (msec) 1684.1 ± 2622.1 2016.5 ± 3191.1 0.818
HF (msec) 4601.1 ± 6561.2 3312.0 ± 4369.3 0.378
Tp-e (msec) 91.8 ± 16.2 99.1 ± 11.6 0.048
QTc (msec) 340.0 ± 42.8 352.7 ± 62.2 0.105
Tp-e/QTc 0.271 ± 0.04 0.282 ±0.04 0.562
Resistance (Ω) 517.6 ±139.6 503.6 ± 172.9 0.018
Reactance (Ω) 41.5 ± 19.5 38.5 ± 18.3 0.160
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FIGURE 1. Descriptive 
Analisys of the Tpeak to 
Tend index in the group 
treated with intravenous 
ferrous gluconate therapy 
63 mg/day (in saline solution 
500 mL).
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FIGURE 2. Descriptive 
Analysis of the Bioelectrical 
Impedence Analysis 
(BIA) in the group treated 
with intravenous ferrous 
gluconate therapy 63 mg/day 
(in saline solution 500 mL).
population is often exposed to adverse events 
related to intravenous iron therapy. These events 
can be related to injection site, such as phlebitis 
and thrombophlebitis, and/or can increase the 
risk of allergic reactions and/or aggravate pre-
existing conditions such as heart failure or renal 
failure.
The results showed treatment efficacy 
(TABLE 1) and safety (TABLE 3) of the oral 
iron formulation. In particular, data pointed out 
the real superiority of the oral administration 
about the cardiovascular risk analysed exploring 
10.4172/clinical-practice.1000471
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the HRV frequency domain in old patients in 
comparison with the intravenous administration 
of ferrous gluconate (FIGURE 3). 
These preliminary results are comfortable 
but not applicable to a broad spectrum of 
patients with secondary anaemia.
Conclusion
This study confirms that Ferric Sodium 
EDTA in combination with vitamin C, folic 
acid, copper gluconate, zinc gluconate and 
selenomethionine (Ferachel forte®) is a valid and 
safe alternative to ferrous gluconate intravenous 
therapy (gold standard) in the treatment of 
secondary anaemia in elderly patients, because 
during the treatment efficacy results has been 
maintained without statistically significant 
variations about cardiovascular risk, evaluated 
exploring the HRV frequency domain. 
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FIGURE 3. Descriptive 
Analysis of the HRV 
High Frequencies 
(p=0.049) explored by 
Regressive Analysis 
in the group treated 
with Ferric Sodium 
EDTA in combination 
with vitamin C, folic 
acid, copper gluconate, 
zinc gluconate and 
selenomethionine 
(Ferachel forte®) 2 tabs/
day for 24 days.
TABLE 3. Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, 
zinc gluconate and selenomethionine (Ferachel forte®) 2 tabs/day for 24 days.
Control Effect p<0.050
fft-LF 2254.5 ± 3471.6 858.0 ± 1140.1 0.145
fft-HF 2704.8 ± 3982.5 883.8 ± 964.9 0.097
fft-TOTAL 8447.1 ± 1746.9 2290.4 ± 2404.5 0.188
fft-LF/HF 0.813 ± 0.589 1.062 ± 0.930 0.335
AR-LF 1817.8 + 2629.3 1024.3 ± 1419.1 0.313
AR-HF 2158.8 ± 2622.4 823.4 ± 810.6 0.049*
AR-TOTAL 6398.6 ± 1012.8 1012.8 ± 3345.5 0.193
AR-LF/HF 0.811 ± 0.659 0.858 ± 0.762 0.806
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